Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $53.00 Average Price Target from Brokerages

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has been assigned a consensus recommendation of “Buy” from the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 1-year price target among analysts that have covered the stock in the last year is $53.00.

DNTH has been the topic of a number of analyst reports. William Blair initiated coverage on shares of Dianthus Therapeutics in a research note on Wednesday, July 2nd. They issued an “outperform” rating on the stock. Robert W. Baird decreased their price target on Dianthus Therapeutics from $58.00 to $50.00 and set an “outperform” rating for the company in a report on Tuesday, May 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a report on Tuesday, May 13th.

Dianthus Therapeutics Stock Up 2.4%

NASDAQ DNTH opened at $20.74 on Friday. The company has a market capitalization of $667.62 million, a price-to-earnings ratio of -6.38 and a beta of 1.43. Dianthus Therapeutics has a twelve month low of $13.36 and a twelve month high of $32.27. The stock has a fifty day simple moving average of $19.49 and a 200 day simple moving average of $20.00.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). The company had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.87 million. Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. Research analysts expect that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

A number of large investors have recently bought and sold shares of the business. TCG Crossover Management LLC acquired a new stake in shares of Dianthus Therapeutics in the 4th quarter valued at about $32,735,000. Vestal Point Capital LP grew its stake in shares of Dianthus Therapeutics by 88.2% in the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after buying an additional 1,499,931 shares during the period. RA Capital Management L.P. grew its stake in shares of Dianthus Therapeutics by 53.6% in the 1st quarter. RA Capital Management L.P. now owns 2,866,733 shares of the company’s stock valued at $52,003,000 after buying an additional 1,000,333 shares during the period. Braidwell LP grew its stake in shares of Dianthus Therapeutics by 144.4% in the 4th quarter. Braidwell LP now owns 1,206,589 shares of the company’s stock valued at $26,304,000 after buying an additional 712,902 shares during the period. Finally, Octagon Capital Advisors LP grew its stake in shares of Dianthus Therapeutics by 20.8% in the 4th quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company’s stock valued at $46,002,000 after buying an additional 363,500 shares during the period. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.